Patents Assigned to Prothena Biosciences Limited
  • Publication number: 20220372118
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • Publication number: 20220275067
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 1, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Philip James DOLAN, III, Tarlochan S. NIJJAR, Svetlana ALEXANDER, Robin BARBOUR, Stephen Jed TAM
  • Patent number: 11345749
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 31, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Patent number: 11237176
    Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 1, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Robin Barbour
  • Patent number: 11191832
    Abstract: The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and/or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 7, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Gene G. Kinney, Theresa Anne Neumann, Daniel Keith Ness
  • Publication number: 20210261652
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 26, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • Patent number: 11028158
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 8, 2021
    Assignees: Prothena Biosciences Limited, University Health Network
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Publication number: 20210130449
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10961302
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 30, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Publication number: 20210077407
    Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
    Type: Application
    Filed: June 23, 2020
    Publication date: March 18, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Patrick GARIDEL, Isaac Craig HENDERSON, Pamela KLEIN
  • Publication number: 20210040188
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: February 11, 2021
    Applicant: Prothena Biosciences Limited
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • Publication number: 20210032319
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: July 20, 2020
    Publication date: February 4, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter SEUBERT, Philip James DOLAN, III, Yue LIU, Robin BARBOUR
  • Publication number: 20210032318
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: April 7, 2020
    Publication date: February 4, 2021
    Applicants: Prothena Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Patent number: 10906964
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 2, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • Patent number: 10906967
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: February 2, 2021
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Publication number: 20210017278
    Abstract: Methods for the treatment of AL amyloidosis associated with the deposition of misfolded immunoglobulin light chain proteins and corresponding uses related to an antibody, such as a 2A4 antibody, or a pharmaceutical formulation comprising the antibody.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 21, 2021
    Applicant: Prothena Biosciences Limited
    Inventors: Tarlochan S. NIJJAR, Philip J. DOLAN, Robin BARBOUR
  • Patent number: 10889638
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10889636
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 12, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Patent number: 10875910
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: December 29, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar